Skip to main content

Table 2 Incidence of diabetes in patients receiving oral anticoagulants after atrial fibrillation

From: Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population‐based cohort study

Treatment Patients, n Median follow-up time (IQR), d Event, n Median time to event (IQR), d Crude incidence per 100 Person-years Weighteda incidence per 100 person-years
All patients
 Warfarin 3454 222 (36–704) 195 126 (16–378) 6.3 6.4
 Apixaban 3335 363 (106–648) 177 174 (43–364) 5.3 4.9
 Dabigatran 4210 363 (84–700) 192 196 (26–413) 4.5 4.3
 Rivaxaban 2689 392 (98–730) 134 199 (36–412) 4.6 5.1
Women
 Warfarin 1551 221 (35–702) 78 154 (31–412) 5.6 5.8
 Apixaban 1699 372 (106–651) 91 198 (46–360) 5.3 5.6
 Dabigatran 2018 364 (78–683) 84 222 (18–423) 4.2 3.9
 Rivaxaban 1282 416 (92–730) 67 186 (34–334) 4.7 5.4
Men
 Warfarin 1903 224 (38–705) 117 90 (8–344) 6.9 7
 Apixaban 1636 348 (106–645) 86 134 (37–372) 5.3 4.1
 Dabigatran 2192 358 (88–714) 108 192 (46–390) 4.8 4.7
 Rivaxaban 1407 378 (102–730) 67 276 (45–480) 4.5 4.7
  1. aInverse probability of treatment weighted